Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership
Complete the form below to unlock access to ALL audio articles.
Rockland Immunochemicals Inc. has announced a new licensing venture with LIMR Development, Inc. (LDI), the business development subsidiary of the Lankenau Institute for Medical Research (LIMR).
Rockland Immunochemicals will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression.
Detailed product information can be found at http://rockland-inc.com/limr-collaboration.aspx.
George Prendergast, PhD, President and CEO of LIMR, stated, “We are proud of the achievement of LDI to generate an agreement with Rockland to commercialize the high-quality research antibodies developed at LIMR.”
"LIMR's work in cancer and inflammation is an elegant fit with Rockland's antibody portfolio and technology platform. We partner with leading institutions to bring to researchers the reagents vital to the advance of their key research. The Philadelphia region is home to some of the world's finest research centers. We are proud to bring the unique scientific and commercial opportunities of the LIMR/LDI/Rockland collaboration to the global research community," commented James Fendrick, President and CEO of Rockland Immunochemicals.
